<?xml version="1.0"?>
<rss version="2.0">
   <channel>
      <title>Hypersensitivity (Team 2) by LEE MING JIE</title>
      <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4</link>
      <description></description>
      <language>en-us</language>
      <pubDate>2024-07-28 00:52:57 UTC</pubDate>
      <lastBuildDate>2024-07-31 16:20:16 UTC</lastBuildDate>
      <webMaster>hello@padlet.com</webMaster>
      <image>
         <url></url>
      </image>
      <item>
         <title>Hypersensitivity </title>
         <author>23033312_2</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062395829</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2024-07-28 00:54:05 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062395829</guid>
      </item>
      <item>
         <title>Type III: immune complex (Ming Jie )</title>
         <author>23033312_2</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062395900</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2024-07-28 00:54:39 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062395900</guid>
      </item>
      <item>
         <title>Initiator </title>
         <author>23033312_2</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452632</link>
         <description><![CDATA[<p>   It is initiated when the allergen- antibody complexes formed by allergen specific IgG or IgM (autoantibody)and autoantigen and are deposited on walls of blood vessels and it cause a series of immune response that cause inflammation. </p><p><br/></p><p>   Before that, the allergen bind specifically to BCR on B cell. B cell present the peptide fragment on MHC class II to the TCR on naive CD4+ T cell. CD4 of  CD4+ T cell bind to MHC class II and B7 of B cell bind to CD28 on the  CD4+ T cell. B cell release cytokine that differentiate CD4+ T cell into follicular T helper cell (TFH). </p><p><br/></p><p>   The TCR and CD4 of TFH is still bound to MHC class II of B cell. The CD40L of T cell bind to CD40 of B cell. A cytokine is released to allow B cell to differentiate into plasma cell that release Immunoglobin G (IgG). This IgG is specific to the epitopes of the allergen. Here, the sensitization of antibody is completed. </p><p><br/></p><p>These paragraphs are inspired by (Elsevier, 2019)</p>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2049043432/e3b9530e5da2f2f8b83bd778ce0de624/image.png" />
         <pubDate>2024-07-28 05:31:22 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452632</guid>
      </item>
      <item>
         <title>component of immune system involved</title>
         <author>23033312_2</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452720</link>
         <description><![CDATA[<p>e.g. allergen specific IgG or IgM, complement protein (C1,C2,C3,C4,C5,C6,C7,C8,C9), neutrophil </p><p><br/></p><p>  After the antigen- antibody complexes is formed and deposited on walls of blood vessels, the C1q bind to Fc receptor of IgG or IgM to initiate the classical pathway of complement system. C1q activate C1r, C1r then activate C1s which will cleave C4 into C4a and C4b. C1s also cleaves C2 into C2a and C2b. C2a bind onto C4b to become C4b2a that cleave C3 into C3a and C3b. C3b land on C4b2a to become C4b2a3b that cleave C5 into C5a and C5b. </p><p><br/></p><p>  C3a , C4a and C5a act as anaphylatoxins that increase the permeability of blood vessel wall. This result in swelling due to leakage of fluid from blood vessels. They are also chemotactic factor that attract neutrophil. The neutrophil degranulates and released lysosomal enzyme resulting in inflammation of blood vessels (vasculitis).</p><p><br/></p><p>These paragraphs are inspired by (Elsevier, 2019)</p>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2049043432/cf426f22374c5d24d4db6bbdda316dc3/image.png" />
         <pubDate>2024-07-28 05:31:59 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452720</guid>
      </item>
      <item>
         <title>Symptoms </title>
         <author>23033312_2</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452760</link>
         <description><![CDATA[<ul><li><p>fever</p></li><li><p>swelling </p></li><li><p>rashes </p></li><li><p>joint pain </p></li><li><p>damage in kidney</p></li></ul><p><br/></p><p>Remarks : symptoms depend on type of tissue affected </p><p><br/></p><p>Inspired by (Osmosis , 2024)</p><p><br/></p><p><br/></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-28 05:32:15 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452760</guid>
      </item>
      <item>
         <title>Reference list </title>
         <author>23033312_2</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452827</link>
         <description><![CDATA[<p>Elsevier, O. f. (Director). (2019). <em>Type III hypersensitivity (immune complex mediated) - causes, symptoms &amp; pathology</em> [Motion Picture]. Retrieved from <a rel="noopener noreferrer nofollow">https://www.youtube.com/watch?v=0T_SAXyMs_c</a></p><p> </p><p>Osmosis . (2024). <em>Type III hypersensitivity</em>. Retrieved from Osmosis: <a rel="noopener noreferrer nofollow">https://www.osmosis.org/learn/Type_III_hypersensitivity</a></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-28 05:32:47 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3062452827</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064042724</link>
         <description><![CDATA[<p><strong>(i)Initiator of Reaction (Khanal, S., &amp; Khanal, S. 2024)</strong></p><p>Hypersensitivity Type I (Also known as immediate Hypersensitivity)</p><p>Definition: Type 1 Hypersensitivity occurs as a result of exposure to an antigen/allergen which involves Immunoglobulin E (IgE) mediated release of antibodies against soluble antigen</p><p>It is also known as immediate sensitivity due to the rapid onset of symptoms following exposure to an allergen.(Reaction Time: Usually appears in a few minutes or within an hour after exposure to antigens) (Abbas, M., Moussa, M., &amp; Akel, H. ,2023)</p><p>1.Sensitization</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exposure to allergen that are breathed or ingested is captured by phagocytes to induce the immune system to produce IgE antibodies specific to the allergen</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When the allergens enter the body they are phagocytosed and processed by lysosome released enzymes into Allergen peptides which are brought to the lymph nodes and presented to Helper T cells(TH).</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TH is now activated and differentiates into TH2 cells which will release interleukins (IL-4,5 and 3) to help B cells undergo class switching to produce IgE antibodies that are specific to the allergens from the standard IgM.</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The need for IgE is due to the high affinity it has for the Fc receptor of mast cells and basophil cells.Thus,they become sensitized when these cells are coated with antibodies</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The IgE Fc regions will bind to the Local mast cells on their Fc receptors and then enter the circulation to bind to Fc receptors on basophils and mast cells</p><p><br></p><p><strong>2.Activation of Mast Cells and basophils(Subsequent exposure to allergen)</strong></p><p><em>&nbsp;</em></p><p><em>(Type 1 hypersensitivity: Immediate - Creative Med Doses</em>. (2019))</p><p>After sensitization on the second exposure to the same allergen, the allergen binds to the fragment antigen-binding(Fab) on two or more bound IgEs on the mast cells which cause a cross-link and activates the mast cells to degranulate mediators(pro-inflammatory molecules),causing an allergic reaction</p><p><br></p><p><strong>3.Release of Mediators( Megha, K., Joseph, X., Akhil, V., &amp; Mohanan, P. (2021):</strong></p><p>Activation of mast cells and mediators ,a signalling cascade event is triggered and a variety of mediators such as Histamine, Pro-inflammtory cytokines etc.</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For example, Histamine binds to receptors on the blood vessel wall to cause vasodilation and Vascular permeability of the blood vessels.</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is the result of inflammation of the skin causing it to be warm due to higher blood flow, Red(higher presence of blood) which are common symptoms of skin allergens due to allergic reactions.</p><p><br></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-30 18:15:04 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064042724</guid>
      </item>
      <item>
         <title>Type 1 HyperSensitivity(Miguel)</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064044479</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2024-07-30 18:17:10 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064044479</guid>
      </item>
      <item>
         <title>Type I Hypersensitivity</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045253</link>
         <description><![CDATA[<p>(ii) Components of Immune system involved</p><p>1.Mast Cells and Basophils</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triggered by allergens to produce histamine and other inflammatory mediators</p><p>Causing itching,redness,swelling and edema</p><p>2.IgE Antibodies</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Produced by class switched B cells</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Specifically bind to allergens and adhere to basophils and mast cells surfaces</p><p>3.Antigen-Presenting Cells(APCs)</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dendritic Cells and etc</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Help in activation and differentiation of Th2 cells (Which then help B cells undergo class switching)</p><p>4.Helper T cells(Th2 Cells)</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Activated Th2 cells release cytokines, interleukins that stimulate B cells to undergo class switching to produce IgE antibodies</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytokine also enhances the growth and activation of mast cells and basophils</p><p>5.Inflammatory mediators</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E.g. Histamine released by mast cell degranulation and basophils</p><p>(iii) Symptoms (Abbas, M., Moussa, M., &amp; Akel, H. ,2023):</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-30 18:19:04 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045253</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045522</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624640717/281099b194982812c8ba6a6c0ac14459/image.png" />
         <pubDate>2024-07-30 18:20:01 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045522</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045650</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624640717/4f23d88fdbfd917a897ae0c5e0c59f12/image.png" />
         <pubDate>2024-07-30 18:20:26 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045650</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045894</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624640717/fd8c93d4c8f4440c366d2d051921f7d5/image.png" />
         <pubDate>2024-07-30 18:21:07 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064045894</guid>
      </item>
      <item>
         <title>Type I Hypersensitivity</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064046689</link>
         <description><![CDATA[<p>(iii) Symptoms (Abbas, M., Moussa, M., &amp; Akel, H. ,2023):</p><p>Type I Hypersensitivities include</p><p>1.Atopic diseases, which is an exaggerated IgE mediated Immune responses</p><p>&gt;Allergic:Asthma,rhinitis,conjunctivitis and dermatitis</p><p>&nbsp;2.Allergic diseases, Which are immune responses to foreign allergens</p><p>&gt;Anaphylaxis,urticaria,angioedema,food,and drug allergies</p><p>Common symptoms that are exhibited in this type of reaction involve vasoactive mediators that is caused by IgE bound mast cells and Basophils:</p><p>&gt;Rash(Inflammation),Hives,erythema,pruritis,edema,flushing,bronchospasm,wheezing,rhinitis and gastrointestinal symptoms(abdominal cramping)</p><p>1.Edema</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling caused by fluid retention that is commonly found to occur the feet, legs or ankles, however it can also occur in the hands, face or any other parts of the body as well.</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mast Cell activation and degranulation to produce histamine in response to an allergen in the dermis causes hyperpermeability of microvasculature allowing fluid to leak into surrounding tissues (Brainly(N.D))</p><p>2.Bronchoconstriction</p><p>Caused by the release of mediators such as histamine and affected tissues</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Histamine causes bronchoconstriction directly by stimulating the H-1 receptor on the airway smooth muscle</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Histamine causes bronchoconstriction indirectly by stimulating afferent vagal fibers in airways leading to the possibility of respiratory disease (Leff, A. (1982)</p><p>3.Inflammation</p><p>Caused by anaphylactic response mediated by IgE antibodies</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The antibodies bind to mast cells and basophils, which are activated to undergo degranulation, producing granules which causes Vasodilation where more blood is able to flow through the blood vessels and Vascular permeability where fluids leaks out of the Blood vessels to the site of infection the resultant is the hallmarks of inflammation such as redness and Swelling. (Theoharides, T. C. et at al. (2012))</p><p>·&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Presence of Skin bump and redness reactions are hallmarks of IgE mediated reactions</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-30 18:23:19 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064046689</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064046988</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624640717/acee02e64e072d9430890dab4d5839dd/image.png" />
         <pubDate>2024-07-30 18:24:18 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064046988</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064047017</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624640717/45a14210da3a4652bc5bb4f48804af15/image.png" />
         <pubDate>2024-07-30 18:24:24 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064047017</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064047040</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624640717/d537858e84cccf6b487bd7ea4a60633d/image.png" />
         <pubDate>2024-07-30 18:24:28 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064047040</guid>
      </item>
      <item>
         <title>Type I hypersensitivity References</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064047353</link>
         <description><![CDATA[<p>References:</p><p>Khanal, S., &amp; Khanal, S. (2024, February 28).&nbsp;<em>Hypersensitivity type I: mechanism and clinical manifestation</em>. Microbe Online.&nbsp;Available at <a rel="noopener noreferrer nofollow">https://microbeonline.com/hypersensitivity-type-i/</a> (Accessed 30 July 2024)</p><p>Abbas, M., Moussa, M., &amp; Akel, H. (2023, July 17).&nbsp;<em>Type I hypersensitivity reaction</em>. StatPearls - NCBI Bookshelf.&nbsp;Available at <a rel="noopener noreferrer nofollow" href="https://www.ncbi.nlm.nih.gov/books/NBK560561/">Type I Hypersensitivity Reaction - StatPearls - NCBI Bookshelf (</a><a rel="noopener noreferrer nofollow">nih.gov</a><a rel="noopener noreferrer nofollow" href="https://www.ncbi.nlm.nih.gov/books/NBK560561/">)</a> (Accessed 30 July 2024)</p><p>Megha, K., Joseph, X., Akhil, V., &amp; Mohanan, P. (2021). Cascade of immune mechanism and consequences of inflammatory disorders.&nbsp;Available at <a rel="noopener noreferrer nofollow">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373857/</a> (Accessed 30 July 2024)</p><p><em>Type 1 hypersensitivity: Immediate - Creative Med Doses</em>. (2019, November 20). Creative Med Doses.&nbsp;Available at <a rel="noopener noreferrer nofollow">https://creativemeddoses.com/topics-list/type-1-hypersensitivity-immediate/</a> (Accessed 30 July 2024)</p><p>Pollard-Smith, T. (2017, November 24).&nbsp;<em>The Greatest Debate of Them All - part 1: Ice - Open Health Clinic</em>. Open Health Clinic.&nbsp;Available at <a rel="noopener noreferrer nofollow">https://openhealthclinic.com/the-greatest-debate-of-them-all-part-1-ice/</a> (Accessed 30 July 2024)</p><p>OpenStax. (2019, December 1).&nbsp;<em>15.1 hypersensitivities</em>. Pressbooks.&nbsp;Available at <a rel="noopener noreferrer nofollow">https://open.oregonstate.education/microbiology/chapter/19-1hypersensitivities/</a> (Accessed 30 July 2024)</p><p>Leff, A. (1982). Pathogenesis of asthma. <em>CHEST Journal</em>, <em>81</em>(2), 224–229. Available at <a rel="noopener noreferrer nofollow">https://pubmed.ncbi.nlm.nih.gov/6276107/#:~:text=Histamine%20may%20act%20directly%20to%20cause%20bronchoconstriction%20by,by%20stimulation%20of%20afferent%20vagal%20fibers%20in%20airways</a>. (Accessed 30 July 2024)</p><p>Brainly(N.D)In a hypersensitivity reaction,what produces edema?.Available at <a rel="noopener noreferrer nofollow">https://brainly.com/question/37875258</a> (Accessed 30 July 2024)</p><p>Theoharides, T. C., Alysandratos, K., Angelidou, A., Delivanis, D., Sismanopoulos, N., Zhang, B., Asadi, S., Vasiadi, M., Weng, Z., Miniati, A., &amp; Kalogeromitros, D. (2012). Mast cells and inflammation.&nbsp;<em>Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease</em>,&nbsp;<em>1822</em>(1), 21–33.&nbsp;Available at <a rel="noopener noreferrer nofollow">https://pubmed.ncbi.nlm.nih.gov/21185371/</a> (Accessed 30 July 2024)</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-30 18:25:31 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064047353</guid>
      </item>
      <item>
         <title>Type II Hypersensitivity (Keerthana)</title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064172905</link>
         <description><![CDATA[<p>aka Cytotoxic Hypersensitivity (Antibody-dependent killing)</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 00:33:16 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064172905</guid>
      </item>
      <item>
         <title>Initiator of reaction</title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064177622</link>
         <description><![CDATA[<p>Type II Hypersensitivity reactions are initiated by an <strong>antibody-mediated immune reaction</strong> in which antibodies <strong>Ig G and Ig M </strong>are directed against endogenous or exogenous antigens. </p><p><br></p><p>--&gt;<strong>Antibody </strong>binds directly to antigen of cell membrane to<strong> activate </strong>the <strong>complement response</strong></p><p>--&gt;complement proteins are circulating protein that when activated lead to an inflammatory response against a particular target</p><p>--&gt;AB mediated response against Ag on the surface of cell membrane</p><p><br></p><p>Examples of antigens: Penicillin, hydrochlorothiazide, quinine, rhesus antigens on the surface of red blood cells</p><p><br></p><p><br></p><p>In reference, to what we have learnt from lesson 4, </p><p>Both<strong> Ig G and Ig M</strong> can <strong>activate</strong> the <strong>compliment system which causes:</strong></p><ol><li><p>Increase in inflammatory mediators</p></li><li><p>Opsonization--&gt;Phagocytosis</p></li><li><p>Membrane Attack Complex (MAC)</p></li><li><p>Natural Killer (NK) cells (ADCC) (IgG)</p></li></ol><p><br></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 00:38:33 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064177622</guid>
      </item>
      <item>
         <title>Components of immune system involved</title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064178217</link>
         <description><![CDATA[<p><strong>Humoral components involved: </strong></p><p>-<strong>Complement proteins (innate)</strong> for activation of classical pathway of complement proteins</p><p>-<strong>Antibodies Ig G and Ig M (adaptive</strong>) from B cells for antibody-mediated cellular dysfunction</p><p><br></p><p><strong>Cellular components involved:</strong></p><p>-<strong>NK cells (innate)</strong> during ADCC</p><p>-<strong>Phagocytes </strong>such as <strong>neutrophils </strong>and <strong>macrophages (innate) </strong>during opsonization </p><p>-<strong>Mast cells </strong>and <strong>basophils (innate)</strong> during inflammatory responses</p><p><br></p><p><strong>Classical Pathway of Type II Hypersensitivity: </strong></p><ol><li><p>Antibody(Ab) binds to antigen via its Fragment Antigen Binding (Fab) region</p></li><li><p>Globular head of C1q recognizes the Fc region of the Ab (Ig G/Ig M) </p></li><li><p>C1q activates C1r which is the inactive serine protease that then activates the C1s to active form</p></li><li><p>C1s then cleaves C4 into C4a and C4b and C2 into C2a and C2b. C4b lands on the antigen presenting cell and C2a lands on the C4b forming C3 convertase. </p></li><li><p>C3 convertase cleaves C3 into C3a and C3b. C3b then sits on the C3 convertase forming C5 convertase ( C4b2a3b).</p></li><li><p>C5 convertase cleaves C5 into C5a and C5b </p></li><li><p>C5b recruits C6 and C7. C7 binds to the surface of the antigen presenting cell. C8 is inserted into the membrane </p></li><li><p>C8 recruits about 10 to 16 pieces of C9 and forms Membrane Attack Complex <strong>(MAC) --&gt;causing the lysis of the cell </strong></p></li></ol><p><br></p><p><strong>Opsonization occurs: </strong></p><p>--&gt;C3b can land on the cell membrane (APC) to act as an opsonin which will allow the phagocytes to recognize the APC more easily for opsonization. Thus, increasing the rate of phagocytosis.</p><p><br></p><p><strong>Increase in Inflammatory mediators: </strong></p><p>--&gt;C3a,C4a,C5a are anaphylatoxins that can bind to the receptors of the mast cell</p><p>--&gt;increases permeability of the wall of blood vessels</p><p>--&gt;vasodilation</p><p>--&gt;Neutrophils leaves blood vessels via extravasation</p><p>--&gt;increase inflammation causing infection</p><p><br></p><p><br></p><p><strong>Antibody dependent Cellular Toxicity (ADCC</strong>) is activated by <strong>Ig G:</strong></p><ol><li><p>Natural Killer(NK) cells detect the antigen-antibody complexes via the Fragment crystallizable (Fc) region of the Ab and becomes activated</p></li><li><p>NK cells then release perforins to punch holes on the host cell and granzymes to trigger apoptosis.</p></li></ol><p><br></p><p><br></p><p><br></p><p><br></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 00:39:42 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064178217</guid>
      </item>
      <item>
         <title>Symptoms</title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064178849</link>
         <description><![CDATA[<p>-Fever</p><p>-Fatigue</p><p>-Weakness</p><p>-Joint pain</p><p>-Skin rashes</p><p><br/></p><p><strong>Hemolytic anemia:</strong> Fatigue, weakness, pale skin, jaundice --&gt;caused by low oxygen carrying and may lead to heart failure</p><p><strong>Goodpasture syndrome:</strong> Hemoptysis (coughing up blood), kidney problems</p><p><strong>Myasthenia gravis:</strong> Muscle weakness and fatigue</p><p><strong>Increase in bilirubin formation</strong> due to hemolysis causes jaundice and may lead to kernicterus.</p><p><br/></p><p><br/></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 00:40:28 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064178849</guid>
      </item>
      <item>
         <title></title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064274305</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://www.youtube.com/watch?v=Em0Wi07dj4E" />
         <pubDate>2024-07-31 02:44:52 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064274305</guid>
      </item>
      <item>
         <title>References for Hypersensitivity Type II</title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064286403</link>
         <description><![CDATA[<p><br></p><p><br></p><ol><li><p>Jeffery, Actor. K (2023) <em>Chapter 8 : Immune hypersensitivities</em>. Available at <a rel="noopener noreferrer nofollow" href="https://www.sciencedirect.com/science/article/abs/pii/B9780443153075000111">https://www.sciencedirect.com/science/article/abs/pii/B9780443153075000111 (Assessed on 31 July 2024)</a></p></li><li><p>James. W, Nelson. L (2013) <em>Type II Hypersensitivities reactions. Available at </em>https://www.sciencedirect.com/topics/medicine-and-dentistry/type-ii-hypersensitivity (Assessed on 31 July 2024)</p></li><li><p>Hasudungan, Armando. (2019 December 4). <em>Hypersensitivity Type II (Cytotoxic reaction) - causes, pathophysiology, complement system </em>[YouTube] Available at <a rel="noopener noreferrer nofollow" href="https://www.youtube.com/watch?v=Em0Wi07dj4E">https://www.youtube.com/watch?v=Em0Wi07dj4E</a> (Assessed on 31 July 2024)</p></li></ol><p><br></p><p><br></p><p><br></p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 03:01:43 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064286403</guid>
      </item>
      <item>
         <title>Type IV hypersensitivity (Edriacia)</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064322748</link>
         <description><![CDATA[<p>delayed type of hypersensitivity </p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 03:53:59 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064322748</guid>
      </item>
      <item>
         <title>Cell components involved </title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064333294</link>
         <description><![CDATA[<ol><li><p><strong>APCS</strong> --&gt; present the peptide fragment to the naïve CD4+ T cells in the lymph node via MHC II which will bind to the TCR and then the co-receptor of the naive CD4+ and then the cd28 of the naïve CD4 T cell will bind to the B7 co-receptor of the dendritic cell. The APC will release cytokine also known as IL-12 to signal the naïve T cell to mature and differentiate into Th1 cell</p></li><li><p><strong>Effector Th1 cell </strong>--&gt; releases ILF-2 to help cells within the area to proliferate and releases inferior gamma to activate phagocytes such as macrophages</p></li><li><p><strong>Macrophages</strong> --&gt; releases proinflammatory cytokines such as TNF, IL-1 and IL-6, which causes leaky endothelial barriers to allow more immune cells in the area to induce immune response against the antigen --&gt; they will also release lysosomal enzymes, complement components and ROS into the exposed area leading to tissue damage </p></li><li><p><strong>CD8+ T cells</strong> --&gt; Cytkines secreted by Th1 will also activate naive CD8+ T cells. Peptide fragment is presented by MHC1 which is present on all nucleated cells in the body and will bind to the TCR of the naïve CD8+ T cells which will release perforin and granzymes to induce apoptosis inside the infected cell Macrophages</p></li></ol>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 04:09:51 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064333294</guid>
      </item>
      <item>
         <title>Initiator of the reaction</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064347523</link>
         <description><![CDATA[<p>Is triggered when T lymphocytes (T helper and cytotoxic) is sensitized to an allergen such as environmental harmless protein (Urushiol - poison ivy), infectious agent from tuberculin skin test (PPD) and chemicals such as nickel which takes 48-72 hours/2-3 days to recruit effector T lymphocytes to cells to the site of exposure. They are also known as contact dermatitis. </p><p><br/></p><p>sensitisation phase: Antigen-presenting cells (APCs) such as macrophages and dendritic cells encounter the allergen, processes it by engulfing it to release peptide fragments, and present it on their surface via Major Histocompatibility Complex (MHC) class II molecules. The peptide fragments on the MHC class II complex of the APC is recognized by the T-cell receptor (TCR) on naïve CD4+ T helper cells, and the CD4 co-receptor on the T helper cell binds to the B7 molecules on the APC. This interaction triggers the APC to release cytokines, such as interleukin-12 (IL-12), which stimulate the proliferation and differentiation of the naïve CD4+ T cells into effector T helper 1 (effector Th1) cells.</p><p><br/></p><p>In the effector phase, subsequent exposure to the same antigen induces a delayed-type hypersensitivity response. Effector CD4+ T helper cells secrete cytokines like interleukin-2 (IL-2) and interferon-gamma (IFN-γ), which promote the release of additional effector Th1 cytokines, further mediating the immune response by activating macrophages and other inflammatory cells. Activated macrophages release pro-inflammatory cytokines such as tumour necrosis factor (TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6), increasing endothelial permeability and allowing more immune cells to enter the affected area. Macrophages also secrete lysosomal enzymes, complement components, and reactive oxygen species which will affect surrounding cells, leading to tissue damage. Additionally, activated CD8+ T cells  directly destroy target cells presenting the peptide fragment of the allergen via MHC class I molecules by releasing perforin and gramzymes to the target infected cell carrying the peptide fragment. In dealing with certain intracellular pathogens, macrophages may transform into multinucleated giant cells to better contain the pathogens.</p>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624563209/3d6d7179b1952c42b78bcb216b4496fe/image.png" />
         <pubDate>2024-07-31 04:28:48 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064347523</guid>
      </item>
      <item>
         <title>Symptoms</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064348904</link>
         <description><![CDATA[<p>Lysosomal enzymes and ROS being released by phagocytes such as macrophages to the inflamed area can lead to tissue damage of the skin --&gt; leading to edema (swelling) and rash/redness and even fever</p><p>When Th1 cells migrate to the injection site, where the bacterium Mycobacterium tuberculosis has been injected into the skin, an inflammatory response is triggered, resulting in induration (hard and thickened skin).</p><p><br/></p><p><br/></p>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624563209/02d9de754feb5d0cc677bb24e7bc7bc2/image.png" />
         <pubDate>2024-07-31 04:30:43 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064348904</guid>
      </item>
      <item>
         <title></title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064359729</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2621384896/c1b98b6796af9c8563424194c7cd1138/image.png" />
         <pubDate>2024-07-31 04:47:46 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064359729</guid>
      </item>
      <item>
         <title>Example</title>
         <author>keerth9n9</author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064506422</link>
         <description><![CDATA[<p>Rhesus incompatibility: </p><p><strong>Hemolytic Disease of the newborn. </strong></p><p>--&gt;Mother is Rh –ve while father is Rh +ve and the first child is also Rh +ve. </p><p>--&gt;During the delivery of the first child, some Rh + fetal blood cells may have entered the <strong>Rh-ve mother’s bloodstream, sensitizing her immune system.</strong> Thus, the mother’s immune system will <strong>produce Rh antibodies against the Rh D antigen.</strong> --&gt;During second pregnancy the <strong>Rh antibodies can diffuse through the placenta and attack the Rh-positive red blood cells</strong> of the <strong>fetus</strong> causing anemia which are lysis of red blood cells in the second baby.</p><p><br></p>]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2621384896/125ffe1f553135fe281fb00576bc29f8/image.png" />
         <pubDate>2024-07-31 09:09:49 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064506422</guid>
      </item>
      <item>
         <title>References</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064541893</link>
         <description><![CDATA[<ol><li><p>Humphrey, J. H. and Perdue, . Samuel Scott (2023, June 29). immune system disorder. Encyclopedia Britannica. <a rel="noopener noreferrer nofollow" href="https://www.britannica.com/science/immune-system-disorder">https://www.britannica.com/science/immune-system-disorder (accessed on 31 July 2024)</a></p></li><li><p>Jeffery K. (2012, March 21) 7 - Adaptive Immune Response and Hypersensitivity <a rel="noopener noreferrer nofollow" href="https://www.sciencedirect.com/science/article/abs/pii/B9780323074476000077">https://www.sciencedirect.com/science/article/abs/pii/B9780323074476000077e Response and Hypersensitivity - ScienceDirect</a> (accessed on 31 July 2024)</p></li><li><p>Marwa K, Kondamudi NP. (2023 Aug 12) Type IV Hypersensitivity Reaction <a rel="noopener noreferrer nofollow" href="https://pubmed.ncbi.nlm.nih.gov/32965899/">https://pubmed.ncbi.nlm.nih.gov/32965899/ </a>(accessed on 31 July 2024)</p></li><li><p>Paul W. Snyder (2017, February 17) Chapter 5 - Diseases of Immunity<a rel="noopener noreferrer nofollow" href="https://www.sciencedirect.com/science/article/abs/pii/B9780323357753000059">https://www.sciencedirect.com/science/article/abs/pii/B9780323357753000059</a>&nbsp;(accessed on 31 July 2024)</p></li><li><p>Aryal S. (2023, June 11) Type IV (Cell Mediated) Hypersensitivity- Mechanism and Examples <a rel="noopener noreferrer nofollow" href="https://microbenotes.com/type-iv-cell-mediated-hypersensitivity-mechanism-and-examples/">https://microbenotes.com/type-iv-cell-mediated-hypersensitivity-mechanism-and-examples/  </a>(accessed on 31 July 2024)</p></li><li><p>LibreTexts (n.d) 12.4E: Type IV (Delayed Cell-Mediated) Reactions <a rel="noopener noreferrer nofollow" href="https://bio.libretexts.org/Bookshelves/Microbiology/Microbiology_(Boundless)/12%3A_Immunology_Applications/12.04%3A_Immunity_Disorders-_Hypersensitivity/12.4E%3A_Type_IV_(Delayed_Cell-Mediated)_Reactions">https://bio.libretexts.org/Bookshelves/Microbiology/Microbiology_(Boundless)/12%3A_Immunology_Applications/12.04%3A_Immunity_Disorders-_Hypersensitivity/12.4E%3A_Type_IV_(Delayed_Cell-Mediated)_Reactions </a>(accessed on 31 July 2024)</p></li><li><p>Krouse John H. (2009, May 15) Chapter 1 - Introduction to Allergy&nbsp; <a rel="noopener noreferrer nofollow" href="https://www.sciencedirect.com/science/article/abs/pii/B9781416036777500054">https://www.sciencedirect.com/science/article/abs/pii/B9781416036777500054 </a>(accessed on 31 July 2024)</p></li><li><p>Abbas M, Moussa M, Akel H. (2023, July 17) Type I Hypersensitivity Reaction. <a rel="noopener noreferrer nofollow" href="https://www.ncbi.nlm.nih.gov/books/NBK560561/#:~:text=Type%20IV%20hypersensitivity%20is%20also,release%2C%20leading%20to%20tissue%20damage">https://www.ncbi.nlm.nih.gov/books/NBK560561/#:~:text=Type%20IV%20hypersensitivity%20is%20also,release%2C%20leading%20to%20tissue%20damage</a>. (accessed on 31 July 2024)</p></li></ol>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 10:20:38 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064541893</guid>
      </item>
      <item>
         <title></title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064574084</link>
         <description><![CDATA[]]></description>
         <enclosure url="https://padlet-uploads.storage.googleapis.com/2624563209/c59b78913848f16476e57581d08e429b/image.png" />
         <pubDate>2024-07-31 11:41:17 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064574084</guid>
      </item>
      <item>
         <title>Treatments</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064660210</link>
         <description><![CDATA[]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 14:19:12 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064660210</guid>
      </item>
      <item>
         <title>Type I</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064668897</link>
         <description><![CDATA[<p>Epinephrine is a common treatment against Type I hypersensitivity. As type I hypersensitivity is immediate and mediated by IgE antibodies. IgE triggers the degranulation of mast cells which releases histamine into the blood stream, causing it to be leaky to increase the movement of immune cells but an excess of histamine causes blood pressure to drop, the formation of hives, airways to narrow and can lead to anaphylactic shock which can be fatal. Epinephrine reduces the effects by counteracting histamine and increasing blood flow and widening airways. It is usually delivered through a shot such as Epipen. It is advised for anyone that could suffer from something as severe as anaphylactic shock to carry one around with them at all times.</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 14:31:48 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064668897</guid>
      </item>
      <item>
         <title>Type II</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064688145</link>
         <description><![CDATA[<p>Immunosuppressants are typically given to treat Type II hypersensitivity. Rituximab is one such immunosuppressant prescribed to those with autoimmune hemolytic anemia, goodpasture syndrome or Graves' disease. It targets CD20, a surface antigen on B cells.</p><p><br></p><p>When an Rh- mother is pregnant with a Rh+ child. The mother's own immune cells recognises the rhesus factor on the fetus' red blood cells as foreign and thus triggers an immune response to destroy the fetus' red blood cells. Taking in anti-RH antibodies during labour and delivery of the child prevents rhesus negative sensitization, which could've led to hemolytic disease of the newborn.</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 14:59:34 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064688145</guid>
      </item>
      <item>
         <title>Type III</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064692374</link>
         <description><![CDATA[<p>Immunosuppressants, anti-inflammatory drugs and steroids are common treatments for type III hypersensitivity. This type of hypersensitivity often leads to nephritis or arthritis wherein excessive inflammatory responses to where the immune complex are deposited causes harm to healthy tissue.</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 15:06:22 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064692374</guid>
      </item>
      <item>
         <title>Type IV</title>
         <author></author>
         <link>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064692966</link>
         <description><![CDATA[<p>Often leading to eczema or skin rashes, type IV hypersensitivity is treated with corticosteroids for dermatitis to treat rashes caused by contact with substances that trigger type IV hypersensivity. Corticosteroids have an anti-inflammatory effect. The triggering substance can usually be avoided though. </p><p><br></p><p>Hypersensitivity therapy can also help to reduce the effects of type IV hypersensitivity through exposure of limited amounts of triggering substance, gradually allowing the body to stop recognising it as a threat and not provoke an immune response.</p>]]></description>
         <enclosure url="" />
         <pubDate>2024-07-31 15:07:33 UTC</pubDate>
         <guid>https://padlet.com/23033312_2/ttsu2ul2exo2mpp4/wish/3064692966</guid>
      </item>
   </channel>
</rss>
